Inhibition of IGF-1R in adrenocortical carcinoma

Other secondary endpoints, including the proportion of patients achieving disease control and duration of disease control were not statistically assessed after no change was noted in overall survival and progression-free survival. [...]despite the hope from the adrenocortical carcinoma community that this drug would succeed, the objective evidence does not support its use at this point. [...]despite poor efficacy, the drug has a favourable toxicity profile, so it might still have a role in combination therapy.